Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAK | O14976 | 1/20 | 0.47 |
| ▸ | RIPK2 | O43353 | 7/20 | 0.43 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.43 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | SYK | P43405 | 2/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12367211 | 0.84 | HTR1A (0.41) | SLC22A12KCNH2SMN1; SMN2 | |
| SCHEMBL591544 | 0.82 | IDO1 (0.45) | GAKSLC22A12 | |
| SCHEMBL26317970 | 0.82 | GAK (0.64) | GAKRIPK2KDRRETMAPK14 | |
| SCHEMBL632944 | 0.82 | LMNA (0.52) | GAKRIPK2SLC22A12SMN1; SMN2 | |
| SCHEMBL3851998 | 0.81 | SLC22A12 (0.56) | GAKRIPK2SLC22A12 | |
| SCHEMBL26632797 | 0.81 | NR4A2 (0.45) | GAKRIPK2SLC22A12SMN1; SMN2 | |
| SCHEMBL22492353 | 0.81 | GAK (0.44) | GAKRIPK2KDRMAPK14SLC22A12 | |
| SCHEMBL31219975 | 0.80 | FYN (0.40) | GAKRIPK2KDRMAPK14SYK | |
| SCHEMBL14999154 | 0.80 | SRC (0.39) | SLC22A12SMN1; SMN2 | |
| SCHEMBL4853499 | 0.80 | SLC2A1 (0.42) | SLC22A12SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160060222-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2016-03-03 | — | — | US | disclosed |
| EP-2566477-B1 | AMINO-QUINOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2015-09-02 | — | — | EP | disclosed |
| EP-2566477-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | Glaxo Group Limited (GB) | 2013-03-13 | — | — | EP | disclosed |
| US-20130053375-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED | 2013-02-28 | — | — | US | disclosed |
| WO-2011140442-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060222-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | ABL1, MAP3K2, MAP4K2 | GAK 162/4885RIPK2 326/4885KDR 404/4885 |
| US-20130053375-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | ABL1, MAP3K2, MAP4K2 | GAK 162/4885RIPK2 326/4885KDR 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.